188 related articles for article (PubMed ID: 20379837)
1. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma.
Shimada M; Sugimoto K; Iwahashi S; Utsunomiya T; Morine Y; Imura S; Ikemoto T
J Gastroenterol; 2010 Aug; 45(8):896-902. PubMed ID: 20379837
[TBL] [Abstract][Full Text] [Related]
2. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis.
Thanan R; Pairojkul C; Pinlaor S; Khuntikeo N; Wongkham C; Sripa B; Ma N; Vaeteewoottacharn K; Furukawa A; Kobayashi H; Hiraku Y; Oikawa S; Kawanishi S; Yongvanit P; Murata M
Free Radic Biol Med; 2013 Dec; 65():1464-1472. PubMed ID: 23917144
[TBL] [Abstract][Full Text] [Related]
3. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma.
Fan L; He F; Liu H; Zhu J; Liu Y; Yin Z; Wang L; Guo Y; Wang Z; Yan Q; Huang G
BMC Cancer; 2011 Jul; 11():320. PubMed ID: 21798073
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CD133+ parenchymal cells in the liver: histology and culture.
Yoshikawa S; Zen Y; Fujii T; Sato Y; Ohta T; Aoyagi Y; Nakanuma Y
World J Gastroenterol; 2009 Oct; 15(39):4896-906. PubMed ID: 19842219
[TBL] [Abstract][Full Text] [Related]
5. Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1α for Intrahepatic Cholangiocarcinoma.
Ohta S; Morine Y; Imura S; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Wada Y; Yamashita S; Bando Y; Shimada M
Anticancer Res; 2019 Nov; 39(11):6025-6033. PubMed ID: 31704828
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma.
Morine Y; Shimada M; Utsunomiya T; Imura S; Ikemoto T; Mori H; Hanaoka J; Kanamoto M; Iwahashi S; Miyake H
Hepatogastroenterology; 2011; 58(110-111):1439-44. PubMed ID: 21940327
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
[TBL] [Abstract][Full Text] [Related]
8. Role of histone deacetylase expression in intrahepatic cholangiocarcinoma.
Morine Y; Shimada M; Iwahashi S; Utsunomiya T; Imura S; Ikemoto T; Mori H; Hanaoka J; Miyake H
Surgery; 2012 Mar; 151(3):412-9. PubMed ID: 21982637
[TBL] [Abstract][Full Text] [Related]
9. Strong expression of CD133 is associated with increased cholangiocarcinoma progression.
Leelawat K; Thongtawee T; Narong S; Subwongcharoen S; Treepongkaruna SA
World J Gastroenterol; 2011 Mar; 17(9):1192-8. PubMed ID: 21448425
[TBL] [Abstract][Full Text] [Related]
10. Role of Central Hypo-enhancement in the Hepatic Arterial Phase of Dynamic Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma.
Teraoku H; Morine Y; Uyama N; Ikemoto T; Iwahashi S; Saito Y; Takasu C; Imura S; Harada M; Shimada M
World J Surg; 2020 Jul; 44(7):2350-2358. PubMed ID: 32152739
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of long non‑coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma.
Bai JG; Tang RF; Shang JF; Qi S; Yu GD; Sun C
Mol Med Rep; 2018 Apr; 17(4):5328-5335. PubMed ID: 29393466
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma.
Tokuda K; Morine Y; Saito Y; Yamada S; Miyazaki K; Yamashita S; Okikawa S; Ikemoto T; Imura S; Shimada M
Int J Clin Oncol; 2020 Dec; 25(12):2083-2089. PubMed ID: 32869120
[TBL] [Abstract][Full Text] [Related]
13. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of microvessel density in intrahepatic cholangiocarcinoma.
Bunsiripaiboon P; Sornmayura P; Wilasrusmee C; Lertsithichai P
J Med Assoc Thai; 2010 Jan; 93(1):66-72. PubMed ID: 20196413
[TBL] [Abstract][Full Text] [Related]
15. CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection.
Morine Y; Imura S; Ikemoto T; Iwahashi S; Saito YU; Shimada M
Anticancer Res; 2017 Oct; 37(10):5701-5705. PubMed ID: 28982889
[TBL] [Abstract][Full Text] [Related]
16. Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.
Morine Y; Shimada M; Utsunomiya T; Imura S; Ikemoto T; Hanaka J; Kanamoto M; Kurita N; Miyake H
Surg Today; 2012 Jan; 42(2):135-40. PubMed ID: 22143355
[TBL] [Abstract][Full Text] [Related]
17. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma.
Guo S; Liu HD; Liu YF; Liu L; Sun Q; Cui XJ
Tumour Biol; 2015 Jan; 36(1):353-64. PubMed ID: 25262276
[TBL] [Abstract][Full Text] [Related]
18. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
Yang SZ; Wang AQ; Du J; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
World J Gastroenterol; 2016 Jul; 22(25):5814-21. PubMed ID: 27433094
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma.
Hirashita T; Iwashita Y; Ohta M; Komori Y; Eguchi H; Yada K; Kitano S
J Gastrointest Surg; 2012 Apr; 16(4):842-8. PubMed ID: 22246855
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers.
Ikeda H; Harada K; Sato Y; Sasaki M; Yoneda N; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Am J Clin Pathol; 2013 Sep; 140(3):329-40. PubMed ID: 23955451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
